See more : Sichuan Chuantou Energy Co.,Ltd. (600674.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Sutro Biopharma, Inc. (STRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sutro Biopharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- S2 Minerals Inc. (STWO.CN) Income Statement Analysis – Financial Results
- Interpark Co., Ltd. (035080.KQ) Income Statement Analysis – Financial Results
- PT United Tractors Tbk (PUTKY) Income Statement Analysis – Financial Results
- DeNA Co., Ltd. (DNACF) Income Statement Analysis – Financial Results
- TOMY Company, Ltd. (TOMYY) Income Statement Analysis – Financial Results
Sutro Biopharma, Inc. (STRO)
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 153.73M | 67.77M | 61.88M | 42.72M | 42.74M | 38.42M | 51.74M | 59.73M |
| Cost of Revenue | 6.82M | 8.29M | 9.77M | 76.96M | 65.61M | 54.26M | 51.90M | 43.55M |
| Gross Profit | 146.92M | 59.48M | 52.11M | -34.24M | -22.88M | -15.84M | -156.00K | 16.18M |
| Gross Profit Ratio | 95.57% | 87.77% | 84.21% | -80.14% | -53.53% | -41.24% | -0.30% | 27.09% |
| Research & Development | 180.43M | 137.17M | 104.40M | 76.96M | 65.61M | 54.26M | 54.64M | 43.55M |
| General & Administrative | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.58M | 59.54M | 56.00M | 36.82M | 32.59M | 21.38M | 16.37M | 14.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -4.35M | 1.91M | -77.00K | 87.00K |
| Operating Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Cost & Expenses | 243.01M | 196.72M | 160.40M | 113.78M | 98.20M | 75.64M | 71.01M | 58.37M |
| Interest Income | 14.51M | 3.46M | 577.00K | 1.51M | 4.07M | 1.62M | 273.00K | 251.00K |
| Interest Expense | 23.75M | 3.35M | 3.14M | 4.08M | 4.35M | 1.62M | 612.00K | 0.00 |
| Depreciation & Amortization | 6.82M | 8.29M | 9.77M | 4.30M | 4.78M | 4.54M | 4.99M | 5.66M |
| EBITDA | -67.92M | -105.07M | -98.52M | -23.75M | -46.62M | -32.82M | -14.09M | 7.36M |
| EBITDA Ratio | -44.18% | -185.16% | -150.46% | -152.74% | -109.08% | -75.89% | -27.22% | 12.33% |
| Operating Income | -89.28M | -128.94M | -98.52M | -71.06M | -55.47M | -37.22M | -19.27M | 1.36M |
| Operating Income Ratio | -58.07% | -190.26% | -159.22% | -166.32% | -129.79% | -96.89% | -37.25% | 2.28% |
| Total Other Income/Expenses | 677.00K | 12.24M | -7.01M | 38.93M | -276.00K | 1.91M | -416.00K | 338.00K |
| Income Before Tax | -88.60M | -116.70M | -105.54M | -32.13M | -55.74M | -35.32M | -19.69M | 1.70M |
| Income Before Tax Ratio | -57.63% | -172.20% | -170.55% | -75.20% | -130.44% | -91.93% | -38.05% | 2.85% |
| Income Tax Expense | 18.19M | 2.50M | 3.14M | 4.08M | 8.68M | 3.53M | 535.00K | 87.00K |
| Net Income | -106.79M | -119.20M | -108.68M | -36.21M | -55.74M | -35.32M | -19.69M | 1.70M |
| Net Income Ratio | -69.47% | -175.89% | -175.62% | -84.75% | -130.44% | -91.93% | -38.05% | 2.85% |
| EPS | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| EPS Diluted | -1.78 | -2.35 | -2.36 | -1.11 | -2.43 | -6.13 | -2.81 | 0.24 |
| Weighted Avg Shares Out | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
| Weighted Avg Shares Out (Dil) | 60.16M | 50.74M | 46.12M | 32.57M | 22.96M | 5.76M | 7.00M | 7.00M |
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma Announces Expansion of Leadership Team
Sutro (STRO) Ovarian Cancer Drug Gets FDA's Fast Track Tag
Sutro Biopharma's Ovarian Cancer Candidate Fast Tracked In US
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference
Sutro Biopharma, Inc. (STRO) Surges 6.4%: Is This an Indication of Further Gains?
Source: https://incomestatements.info
Category: Stock Reports